Fresenius Medical Care Unveils Major Share Buyback Program Worth EUR 1 Billion

Fresenius Medical Care Announces New Share Buyback Initiative

Bad Homburg, Germany – Fresenius Medical Care (FME), recognized as the premier provider of products and services for individuals grappling with renal diseases, has revealed plans for a new share buyback program. This strategic initiative will encompass a substantial total value of around EUR 1 billion, executed in phases over the course of the next 12 months.

The decision to embark on this share buyback program is grounded in the authorization received during the Company’s Annual General Meeting held on May 21, 2026. Operationally, the buyback is anticipated to commence in the near future, shortly after concluding a previous buyback program on April 30, 2026. This movement is in line with FME's capital allocation strategy, which combines regular buybacks with dividend distributions to maintain and enhance shareholder value.

Helen Giza, the CEO and Chair of the Management Board of Fresenius Medical Care AG, stated: "This new share buyback program demonstrates our unwavering commitment to value creation and capital return to our shareholders. The launch of this initiative, following the early completion of our preceding EUR 1 billion buyback, showcases our financial robustness and disciplined execution strategy. It signifies our confidence in our FME Reignite strategy, our business performance, and our outlook for sustainable growth."

Additionally, Martin Fischer, CFO of Fresenius Medical Care, emphasized that this new share buyback plan is a product of robust cash flow generation and rigorous financial management. He asserted that channeling resources into share buybacks not only yields significant returns but also aligns with creating long-term value for shareholders.

Fresenius Medical Care has established itself as a leader in the renal health industry, providing vital services to roughly 4.5 million patients globally who depend on regular dialysis treatments. Through its expansive network of 3,539 dialysis clinics, approximately 290,000 patients benefit from their innovative dialysis products, including machines and dialyzers, further solidifying the Company’s position in the market.

The company’s shares are traded on the Frankfurt Stock Exchange (FME) as well as on the New York Stock Exchange (FMS). For more detailed information about Fresenius Medical Care, shareholders and interested investors can visit their official website at www.freseniusmedicalcare.com.

Looking Ahead

As the share buyback program rolls out, Fresenius Medical Care aims to strengthen its market position amidst growing competition in the healthcare sector. This move reflects the Company's strategic priorities and confidence in its operational capacities.

In summary, Fresenius Medical Care's new share buyback program is more than just a financial maneuver; it is a clear message to investors highlighting the Company’s commitment to sustained value creation and its robust growth trajectory in the dialysis market. As they continue to innovate and expand, stakeholders will be keenly observing the execution of this program and its implications for shareholder value.